Teva Pharmaceutical Industries Ltd.

Major Shareholding Notification • Mar 7, 2018

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden hours
per response	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person		2. Date of Event Requiring	3. Issuer Name and Ticker or Trading Symbol
McClellan	Michael	James	Statement (Month/Day/Year)	Teva Pharmaceutical Industries Ltd. [TEVA]
(Last)	(First)	(Middle) C/O Teva Pharmaceutical Industries Ltd. , 5	01/01/2018		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _ Director _ 10% Owner		5. If Amendment, Date Original
Basel Street							Filed(Month/Day/Year) 01/02/2018
(Street)				X Officer (give title	____ Other (specify below)		6. Individual or Joint/Group Filing (Check
Petach Tikva	L3	4951033		below)	EVP, Chief Financial Officer		Applicable Line) X Form filed by One Reporting Person
(City)	(State)	(Zip)					____ Form filed by More than One Reporting Person
	Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4) Owned				2. Amount of Securities Beneficially	3. Ownership Form: Direct (D)	(Instr. 5)	4. Nature of Indirect Beneficial Ownership

(Instr. 4)	Owned	Form: Direct (D)	(Instr. 5)
	(Instr. 4)	or Indirect (I)
		(Instr. 5)
(1) Ordinary Shares	(2) 10,328.272	D

Table II - Derivative Securities Beneficially Owned ( e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Security: Direct (D) or Indirect (I) (Instr. 5)

Explanation of Responses:

• (1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
• (2) This Amendment to Form 3 filed on January 2, 2018 is being filed solely to correct the number of Ordinary Shares owned by the Reporting Person.

Remarks:

The Reporting Person is filing this form in connection with the Issuer's transition from a foreign private issuer to a domestic issuer, effective January 1, 2018.

/s/ Dov Bergwerk as attorney-in-fact for Michael James McClellan 03/06/2018

**Signature of Reporting Person Date

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.